Clinical Benefit Observed with Pembrolizumab in Heavily Pretreated Classical Hodgkin Lymphoma
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Combination therapy with perifosine and sorafenib effective and safe for the treatment of relapsed or refractory Hodgkin lymphoma.
International group of hematologists released recommendations for evaluation and treatment response to Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
Patients with lymphoma who receive radiation therapy have an increased survival rate.
Para-aortic radiation with ≥36 Gy linked to increased risk of diabetes mellitus.
Hodgkin lymphoma survivors who have developed a second malignancy are at a higher risk of developing a third malignancy.
Post-chemotherapy proton therapy has a similar success rate to more conventional methods.
The largest clinical study to evaluate breast cancer screening of female survivors of childhood Hodgkin lymphoma, showed that MRI detected invasive breast tumors at very early stages, when cure rates are expected to be excellent.
New data show a high prevalence of coronary artery disease among survivors of Hodgkin lymphoma.
Patients with Hodgkin lymphoma who have PET-positive residual disease after chemotherapy and poor tumor shrinkage are at high risk of progression or relapse.